Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide

NCT05129189 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT05129189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05129189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Phase 2
Overall status
Unknown status
Start date
June 29, 2022
Completion date
July 31, 2023
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections